



## NEWS RELEASE

### AdVec Inc. Licenses Adenoviral Vectors and Manufacturing Patent Portfolio to Defyrus Inc.

Web Site Release

January 1, 2011

---

**Toronto** - Defyrus Inc. today announced the signing of an intellectual property licensing agreement with AdVec Inc., a pioneer and world leader in the development and manufacturing of Adenoviral-based gene delivery systems. Under the terms of the agreement, Defyrus accesses a comprehensive portfolio of issued patents that enable freedom-to-operate with AdVec's Ad5 gene delivery systems and their efficient manufacturing in return for a technology access fee, milestone payments and a royalty on product sales.

"AdVec's high performance Ad5 vectors are ideal for our DEF201 antiviral product and our vaccine pipeline line", stated, Dr. Jeffrey Turner, President & CEO, Defyrus Inc., "In addition, these patents represent the leading edge of efficient, large commercial scale Ad5 manufacturing".

"Defyrus and its multinational public health and biodefense collaborators have documented the value and efficacy of Ad5-vectored interferon gene-based drugs to combat a wide range of different viral infections", noted Dr. Frank Graham, President, AdVec.

#### **About Defyrus Inc.**

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs and immune stimulator to improve vaccine performance as medical countermeasures to viral threats of military and public health interest. [www.defyrus.com](http://www.defyrus.com)

#### **About AdVec. Inc.**

AdVec is a privately owned company incorporated in Ontario, Canada since 1996. AdVec is in the business of consulting in the field of biotechnology and in licensing of technologies developed and invented by the directors of the company and by coinventors who have assigned rights to AdVec. AdVec owns over a dozen patents issued worldwide covering development of adenovirus vectors for gene therapy and vaccines.

###

#### **For further information:**

Dr. Jeffrey D. Turner  
President & CEO  
Tel: (613) 674-1138  
info@defyrus.com

Mr. Dana Rath  
Chief Financial Officer  
Tel: (514) 939-2531  
info@defyrus.com